Targeted Protein Degradation and Drug Discovery

WEBINAR

Targeted protein degradation by chimeric small molecules is a novel strategy for drug discovery. Dr. Naito & his team have developed a series of specific and non-genetic IAP-dependent protein erasers (SNIPERs) and proteolysis targeting chimeras (PROTAC^®) against various proteins including estrogen receptor alpha in breast cancers, androgen receptor in prostate cancers, BCR-ABL oncogenic kinase in chronic myelogenous leukemia cells, TACC3 protein overexpressed in various cancer cells, HPGDS and so on. These SNIPERs and PROTAC^® degraders recruit E3 ubiquitin ligases to the target proteins in cells, thereby inducing ubiquitylation and proteasomal degradation of the target proteins. Generally, the degradation is rapid and highly specific to the targets, and the reduced protein level sustains even after drug removal. Substitution of the target ligands allows the development of novel degrader chimeras against the proteins of interest, therefore PROTAC^® degraders and SNIPERs attract attention as a platform technology for novel drug discovery. In addition to the forced ubiquitylation by chimeric molecules, inhibition of de-ubiquitylase also induces targeted degradation of some proteins such as BCR-ABL. In the symposium, Dr. Naito will share an overview of the technologies to induce proteasomal degradation of target proteins, and their application for drug discovery and basic research.

This webinar will cover:

1. Induction of proteasomal degradation of target proteins by chemical compounds including PROTAC^® degraders, SNIPERs and E3 modulators.
2. Advantage of protein degradation over functional inhibition as a drug.
3. How to develop PROTAC^® degraders and SNIPERs against proteins of your interest.
4. Future prospect of the targeted protein degradation as a modarity for novel drug discovery.